Comparison · NCT01582711-720c8eab
3HP Self Administered Therapy (SAT) vs 3HP SAT With SMS Reminders: Treatment Completion Rates Between Participants Randomized to SAT Without Reminders Versus SAT With Weekly SMS Reminders
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. 3HP Self Administered Therapy (SAT) vs 3HP SAT With SMS Reminders: Treatment Completion Rates Between Participants Randomized to SAT Without Reminders Versus SAT With Weekly SMS Reminders. Trial comparisons, record NCT01582711-720c8eab. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01582711-720c8eab
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.74 | 0.691 | 0.784 | wilson | |
| Risk in group 2 | 0.767 | 0.718 | 0.809 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0266 | -0.0919 | 0.0392 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.965 | 0.885 | 1.05 | log | |
| Odds ratio, group 1 over group 2 | 0.867 | 0.608 | 1.24 | log | |
| Number needed to treat, for one fewer participant with the outcome on 3HP Self Administered Therapy (SAT) than on 3HP SAT With SMS Reminders | 37.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | 3HP Self Administered Therapy (SAT) | 900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) as patient Self Administered Therapy (SAT)~Self Administered Therapy (SAT): Self Administered Therapy (SAT)~isoniazid and rifapentine: rifapentine (PRIFTIN, RPT) 900 mg and isoniazid (INH) 900mg, once-weekly, for 12 weeks (12 doses) | 248 | 335 | OG000 |
| Group 2 | 3HP SAT With SMS Reminders | 900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) as patient Self Administered Therapy (SAT). In addition, patient receives phone Short Message Service (SMS) reminders weekly.~Self Administered Therapy (SAT): Self Administered Therapy (SAT)~SMS reminders: Short Message Service (SMS) text reminders~isoniazid and rifapentine: rifapentine (PRIFTIN, RPT) 900 mg and isoniazid (INH) 900mg, once-weekly, for 12 weeks (12 doses) | 250 | 326 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Treatment Completion Rates Between Participants Randomized to SAT Without Reminders Versus SAT With Weekly SMS Reminders
- Description
- To compare the treatment completion rates between participants randomized to SAT without reminders versus SAT with weekly SMS reminders
- Time frame
- Up to 16 weeks from start of treatment.
- Population
Participants analyzed excludes 4 participants (2 in each SAT groups) who were enrolled as contacts of a person with active TB before susceptibility results had returned showing resistance to isoniazid or rifampin in source patient. These participants were excluded from treatment completion analyses.
Source ClinicalTrials.gov
Trial
- Title
- Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT
- NCT number
- NCT01582711
- Phases
- PHASE3
- Conditions
- Latent Tuberculosis Infection
- Interventions
- Self Administered Therapy (SAT), SMS reminders, isoniazid and rifapentine
- Lead sponsor
- Centers for Disease Control and Prevention
- Results first posted
- 2025-03-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01582711?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01582711-720c8eab